Trade Biomerieux - BIM CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.65 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.022096% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.000126% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | EUR | ||||||||
Margin | 5% | ||||||||
Stock exchange | France | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Biomerieux SA ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 100.75 |
Open* | 101.6 |
1-Year Change* | 0.94% |
Day's Range* | 100.15 - 102.6 |
52 wk Range | 84.54-101.80 |
Average Volume (10 days) | 70.20K |
Average Volume (3 months) | 1.64M |
Market Cap | 11.85B |
P/E Ratio | 30.75 |
Shares Outstanding | 118.12M |
Revenue | 3.70B |
EPS | 3.26 |
Dividend (Yield %) | 0.84915 |
Beta | -0.01 |
Next Earnings Date | Mar 14, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 28, 2024 | 101.95 | 2.00 | 2.00% | 99.95 | 102.80 | 99.80 |
Mar 27, 2024 | 100.75 | 0.25 | 0.25% | 100.50 | 101.05 | 99.60 |
Mar 26, 2024 | 100.60 | 0.80 | 0.80% | 99.80 | 100.85 | 99.50 |
Mar 25, 2024 | 100.45 | 0.85 | 0.85% | 99.60 | 101.00 | 99.00 |
Mar 22, 2024 | 99.60 | 0.20 | 0.20% | 99.40 | 99.65 | 98.20 |
Mar 21, 2024 | 100.15 | 0.60 | 0.60% | 99.55 | 100.75 | 99.20 |
Mar 20, 2024 | 98.50 | 0.65 | 0.66% | 97.85 | 99.00 | 97.35 |
Mar 19, 2024 | 98.15 | 0.75 | 0.77% | 97.40 | 98.45 | 96.15 |
Mar 18, 2024 | 97.60 | -0.10 | -0.10% | 97.70 | 98.60 | 97.40 |
Mar 15, 2024 | 97.50 | -0.80 | -0.81% | 98.30 | 99.30 | 96.50 |
Mar 14, 2024 | 99.75 | 2.10 | 2.15% | 97.65 | 100.15 | 94.80 |
Mar 13, 2024 | 100.25 | 1.65 | 1.67% | 98.60 | 100.50 | 98.45 |
Mar 12, 2024 | 98.60 | -0.20 | -0.20% | 98.80 | 99.15 | 98.05 |
Mar 11, 2024 | 98.10 | -0.60 | -0.61% | 98.70 | 98.90 | 97.70 |
Mar 8, 2024 | 99.10 | -0.45 | -0.45% | 99.55 | 100.05 | 98.20 |
Mar 7, 2024 | 99.40 | 0.45 | 0.45% | 98.95 | 99.85 | 98.20 |
Mar 6, 2024 | 99.60 | -1.20 | -1.19% | 100.80 | 101.30 | 98.10 |
Mar 5, 2024 | 102.35 | 0.25 | 0.24% | 102.10 | 102.95 | 102.05 |
Mar 4, 2024 | 102.55 | 0.55 | 0.54% | 102.00 | 103.35 | 102.00 |
Mar 1, 2024 | 102.00 | 0.95 | 0.94% | 101.05 | 102.35 | 100.05 |
Biomerieux Events
Time (UTC) | Country | Event |
---|---|---|
Friday, April 26, 2024 | ||
Time (UTC) 06:30 | Country FR
| Event Q1 2024 Biomerieux SA Corporate Sales Release Q1 2024 Biomerieux SA Corporate Sales ReleaseForecast -Previous - |
Thursday, May 23, 2024 | ||
Time (UTC) 10:59 | Country FR
| Event Biomerieux SA Annual Shareholders Meeting Biomerieux SA Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 3589.1 | 3376.2 | 3118.2 | 2674.8 | 2421.3 |
Revenue | 3589.1 | 3376.2 | 3118.2 | 2674.8 | 2421.3 |
Cost of Revenue, Total | 1580.4 | 1375.4 | 1364.5 | 1208.2 | 1119 |
Gross Profit | 2008.7 | 2000.8 | 1753.7 | 1466.6 | 1302.3 |
Total Operating Expense | 3001.9 | 2591.3 | 2566 | 2304.1 | 2075.2 |
Selling/General/Admin. Expenses, Total | 954.7 | 815.6 | 789.3 | 749.8 | 643.1 |
Research & Development | 446.6 | 385.8 | 398.8 | 374.3 | 326.9 |
Depreciation / Amortization | 76.6 | 59.7 | 17.5 | 17.9 | 17.5 |
Unusual Expense (Income) | -0.6 | 0.6 | |||
Other Operating Expenses, Total | -56.4 | -44.6 | -4.7 | -46.1 | -31.3 |
Operating Income | 587.2 | 784.9 | 552.2 | 370.7 | 346.1 |
Interest Income (Expense), Net Non-Operating | -4.3 | -11.7 | -29.1 | -23.8 | -26.7 |
Other, Net | -2.3 | 1.3 | 1.2 | 0.7 | -1.9 |
Net Income Before Taxes | 580.6 | 774.5 | 524.3 | 347.6 | 317.5 |
Net Income After Taxes | 440.5 | 598.9 | 402.8 | 269.8 | 252.4 |
Minority Interest | 11.8 | 2.9 | 1.7 | 3.1 | 1.1 |
Equity In Affiliates | 0 | -0.7 | -0.2 | 0 | 0.2 |
Net Income Before Extra. Items | 452.3 | 601.1 | 404.3 | 272.9 | 253.7 |
Net Income | 452.3 | 601.1 | 404.3 | 272.9 | 253.7 |
Total Adjustments to Net Income | 0.1 | 0 | 0.1 | -0.1 | 2.8 |
Income Available to Common Excl. Extra. Items | 452.4 | 601.1 | 404.4 | 272.8 | 256.5 |
Income Available to Common Incl. Extra. Items | 452.4 | 601.1 | 404.4 | 272.8 | 256.5 |
Diluted Net Income | 452.4 | 601.1 | 404.4 | 272.8 | 256.5 |
Diluted Weighted Average Shares | 118.441 | 118.893 | 118.592 | 118.609 | 118.203 |
Diluted EPS Excluding Extraordinary Items | 3.81964 | 5.05579 | 3.41 | 2.3 | 2.17 |
Dividends per Share - Common Stock Primary Issue | 0.85 | 0.85 | 0.62 | 0.19 | 0.35 |
Diluted Normalized EPS | 3.81964 | 5.05189 | 3.41389 | 2.3 | 2.17 |
Dilution Adjustment | 0 |
Jun 2023 | Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | |
---|---|---|---|---|---|
Total revenue | 1770.1 | 1931.1 | 1658 | 1802 | 1574.2 |
Revenue | 1770.1 | 1931.1 | 1658 | 1802 | 1574.2 |
Cost of Revenue, Total | 770.9 | 860.4 | 720 | 721.6 | 659.2 |
Gross Profit | 999.2 | 1070.7 | 938 | 1080.4 | 915 |
Total Operating Expense | 1562.3 | 1641 | 1360.9 | 1383.5 | 1208.4 |
Selling/General/Admin. Expenses, Total | 502.1 | 514.4 | 440.3 | 436.9 | 379.6 |
Research & Development | 226.5 | 239.3 | 207.3 | 204.8 | 181.5 |
Depreciation / Amortization | 83.6 | 51.7 | 24.9 | 44.6 | 8.3 |
Other Operating Expenses, Total | -20.8 | -24.8 | -31.6 | -24.4 | -20.2 |
Operating Income | 207.8 | 290.1 | 297.1 | 418.5 | 365.8 |
Interest Income (Expense), Net Non-Operating | 0.9 | 2.8 | -7.1 | -4.7 | -7 |
Other, Net | -0.4 | -3.8 | 1.5 | 1.3 | 0.6 |
Net Income Before Taxes | 208.3 | 289.1 | 291.5 | 415.1 | 359.4 |
Net Income After Taxes | 138.7 | 214.2 | 226.3 | 322 | 276.9 |
Minority Interest | 22.9 | 10 | 1.8 | 1.8 | 1.1 |
Equity In Affiliates | 0 | 0 | 0 | 0.2 | -0.9 |
Net Income Before Extra. Items | 161.6 | 224.2 | 228.1 | 324 | 277.1 |
Net Income | 161.6 | 224.2 | 228.1 | 324 | 277.1 |
Income Available to Common Excl. Extra. Items | 161.6 | 224.4 | 228 | 324 | 277.1 |
Income Available to Common Incl. Extra. Items | 161.6 | 224.4 | 228 | 324 | 277.1 |
Diluted Net Income | 161.6 | 224.4 | 228 | 324 | 277.1 |
Diluted Weighted Average Shares | 118.613 | 118.533 | 118.349 | 119.1 | 118.927 |
Diluted EPS Excluding Extraordinary Items | 1.36241 | 1.89315 | 1.92651 | 2.7204 | 2.33 |
Dividends per Share - Common Stock Primary Issue | 0 | 0.85 | 0 | 0.85 | 0 |
Diluted Normalized EPS | 1.36241 | 1.89315 | 1.92651 | 2.7204 | 2.33 |
Total Adjustments to Net Income | 0.2 | -0.1 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 2216.7 | 2184.6 | 1661.6 | 1438.5 | 1314.4 |
Cash and Short Term Investments | 552.6 | 803.5 | 389.2 | 275 | 288.3 |
Cash | 401.7 | 547.1 | 313.5 | 241 | 239.9 |
Cash & Equivalents | 150.9 | 256.4 | 75.7 | 34 | 48.4 |
Total Receivables, Net | 926.9 | 761 | 730.4 | 668.8 | 607.3 |
Accounts Receivable - Trade, Net | 740.1 | 590.6 | 597.9 | 552.1 | 491.8 |
Total Inventory | 737.2 | 620 | 541.9 | 494.7 | 418.8 |
Other Current Assets, Total | 0.1 | 0.1 | |||
Total Assets | 5186.6 | 4605 | 3927.8 | 3781.9 | 3501.6 |
Property/Plant/Equipment, Total - Net | 1369.9 | 1224.8 | 1068.6 | 1025.2 | 899.1 |
Property/Plant/Equipment, Total - Gross | 2703.9 | 2447.7 | 2173.3 | 2100.9 | 1899.4 |
Accumulated Depreciation, Total | -1334.1 | -1222.7 | -1104.7 | -1075.7 | -1000.5 |
Goodwill, Net | 812.5 | 669.5 | 629.4 | 652.5 | 619 |
Intangibles, Net | 625 | 411.5 | 430.7 | 508.4 | 507.2 |
Long Term Investments | 71.2 | 62 | 39.9 | 31.7 | 59.2 |
Note Receivable - Long Term | 19.8 | 10.7 | 10.4 | 8 | |
Other Long Term Assets, Total | 71.5 | 52.6 | 86.9 | 115.2 | 94.7 |
Total Current Liabilities | 1131.1 | 955.7 | 923.8 | 1170.1 | 796.3 |
Accounts Payable | 269.4 | 239.5 | 207.1 | 211.9 | 179.7 |
Accrued Expenses | 372.6 | 327.4 | 283.3 | 262.4 | |
Notes Payable/Short Term Debt | 23.9 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 163.1 | 99.7 | 128.9 | 438.6 | 129.1 |
Other Current Liabilities, Total | 302.1 | 616.5 | 260.4 | 236.3 | 225.1 |
Total Liabilities | 1582.4 | 1492.8 | 1496.7 | 1578 | 1572.8 |
Total Long Term Debt | 318.4 | 362.8 | 352.4 | 153.7 | 524.9 |
Long Term Debt | 224.7 | 362.8 | 352.4 | 153.7 | 524.9 |
Deferred Income Tax | 53 | 60.3 | 105.8 | 141.2 | 130.5 |
Minority Interest | 38.7 | 51.4 | 50.2 | 50.7 | 74.1 |
Other Liabilities, Total | 41.2 | 62.6 | 64.5 | 62.3 | 47 |
Total Equity | 3604.2 | 3112.2 | 2431.1 | 2203.9 | 1928.8 |
Common Stock | 12 | 12 | 12 | 12 | 12 |
Additional Paid-In Capital | 3062.2 | 2532.1 | 2204.7 | 1933.4 | 1712.2 |
Retained Earnings (Accumulated Deficit) | 410.4 | 542.5 | 344.7 | 207.9 | 210.1 |
Treasury Stock - Common | -36 | -10.3 | -23 | -3.9 | -32.8 |
Other Equity, Total | 155.6 | 35.9 | -107.3 | 54.5 | 27.3 |
Total Liabilities & Shareholders’ Equity | 5186.6 | 4605 | 3927.8 | 3781.9 | 3501.6 |
Total Common Shares Outstanding | 118 | 118.282 | 118.16 | 118.324 | 117.819 |
Capital Lease Obligations | 93.7 |
Jun 2023 | Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | |
---|---|---|---|---|---|
Total Current Assets | 2152.7 | 2216.7 | 2058.4 | 2184.6 | 1798.7 |
Cash and Short Term Investments | 423 | 552.6 | 524.2 | 803.5 | 493.2 |
Cash | 320.2 | 401.7 | 365.6 | 803.5 | 363.3 |
Cash & Equivalents | 102.8 | 150.9 | 158.6 | 129.9 | |
Total Receivables, Net | 888.9 | 926.9 | 825.7 | 761 | 694.5 |
Accounts Receivable - Trade, Net | 657.7 | 740.1 | 624.2 | 590.6 | 542.4 |
Total Inventory | 840.9 | 737.2 | 708.5 | 620 | 611 |
Total Assets | 5030.9 | 5186.6 | 5041.2 | 4605 | 4157.2 |
Property/Plant/Equipment, Total - Net | 1392 | 1369.9 | 1314.4 | 1224.8 | 1135.2 |
Property/Plant/Equipment, Total - Gross | 2782.4 | 2703.9 | 2620.7 | 2447.7 | 2306.1 |
Accumulated Depreciation, Total | -1390.4 | -1334 | -1306.2 | -1222.7 | -1170.8 |
Goodwill, Net | 734.4 | 812.5 | 877.5 | 669.5 | 642.4 |
Intangibles, Net | 592.5 | 625 | 667.5 | 411.5 | 426.8 |
Long Term Investments | 89.2 | 91 | 48 | 62 | 56.6 |
Other Long Term Assets, Total | 70.1 | 71.5 | 75.4 | 52.6 | 97.5 |
Total Current Liabilities | 980.7 | 1131.1 | 1020.7 | 955.7 | 857.9 |
Accounts Payable | 243.5 | 269.4 | 243.4 | 239.5 | 199.1 |
Notes Payable/Short Term Debt | 22.4 | 23.9 | 11 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 138.2 | 163.1 | 215 | 99.7 | 163.2 |
Other Current Liabilities, Total | 576.6 | 674.7 | 551.3 | 616.5 | 495.6 |
Total Liabilities | 1403.6 | 1582.4 | 1572.2 | 1492.8 | 1459 |
Total Long Term Debt | 330.1 | 318.4 | 365.7 | 362.8 | 361.5 |
Long Term Debt | 231.7 | 224.7 | 272 | 362.8 | 361.5 |
Deferred Income Tax | 33.9 | 53 | 97.2 | 60.3 | 124.7 |
Minority Interest | 14.2 | 38.7 | 44.9 | 51.4 | 50.8 |
Other Liabilities, Total | 44.7 | 41.2 | 43.7 | 62.6 | 64.1 |
Total Equity | 3627.3 | 3604.2 | 3469 | 3112.2 | 2698.2 |
Common Stock | 12 | 12 | 12.2 | 12 | 12 |
Additional Paid-In Capital | 3416.3 | 3062.2 | 3174.3 | 2532.1 | 2528.8 |
Retained Earnings (Accumulated Deficit) | 120.2 | 410.4 | 183.5 | 542.5 | 219.5 |
Treasury Stock - Common | -20.9 | -36 | -152.3 | -10.3 | -16.6 |
Other Equity, Total | 99.7 | 155.6 | 251.3 | 35.9 | -45.5 |
Total Liabilities & Shareholders’ Equity | 5030.9 | 5186.6 | 5041.2 | 4605 | 4157.2 |
Total Common Shares Outstanding | 118.124 | 118 | 119.507 | 118.282 | 118.095 |
Other Current Assets, Total | -0.1 | 0.1 | |||
Capital Lease Obligations | 98.4 | 93.7 | 93.7 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 440.5 | 598.2 | 402.7 | 269.7 | 255.6 |
Cash From Operating Activities | 475.1 | 824.7 | 582.8 | 407.9 | 399.7 |
Cash From Operating Activities | 67 | 58.8 | 210.8 | 189.5 | 177 |
Non-Cash Items | 264.8 | 176.7 | 159 | 45.5 | 12.3 |
Cash Taxes Paid | 223.5 | 185.4 | 115.9 | 81.6 | 66.5 |
Cash Interest Paid | |||||
Changes in Working Capital | -297.2 | -9 | -189.7 | -96.8 | -45.2 |
Cash From Investing Activities | -528.1 | -307.3 | -265.2 | -282.2 | -413.1 |
Capital Expenditures | -286.7 | -290.1 | -277.5 | -272.5 | -226.4 |
Other Investing Cash Flow Items, Total | -241.4 | -17.2 | 12.3 | -9.7 | -186.7 |
Cash From Financing Activities | -244.2 | -140.6 | -176.2 | -133.9 | 43 |
Financing Cash Flow Items | -0.1 | -2.4 | -23.4 | 0 | |
Total Cash Dividends Paid | -101.2 | -73.1 | -22.5 | -41.3 | -40.2 |
Issuance (Retirement) of Stock, Net | -157.2 | -17.4 | -16.8 | 0 | -22.3 |
Issuance (Retirement) of Debt, Net | 14.3 | -50.1 | -134.5 | -69.2 | 105.5 |
Foreign Exchange Effects | 38.7 | 39.2 | -34.1 | -6.1 | -11.8 |
Net Change in Cash | -258.5 | 416 | 107.3 | -14.3 | 17.8 |
Dec 2022 | Jun 2022 | Dec 2021 | Jun 2021 | |
---|---|---|---|---|
Net income/Starting Line | 440.5 | 226.2 | 598.2 | 276 |
Cash From Operating Activities | 475.1 | 150.9 | 824.7 | 285.8 |
Cash From Operating Activities | 67 | 100.4 | 58.8 | 97.2 |
Non-Cash Items | 264.8 | -27.4 | 176.7 | -66.4 |
Cash Taxes Paid | 223.5 | 145.4 | 185.4 | 98.1 |
Changes in Working Capital | -297.2 | -148.3 | -9 | -21 |
Cash From Investing Activities | -528.1 | -352.3 | -307.3 | -143.4 |
Capital Expenditures | -286.7 | -152.8 | -290.1 | -143.5 |
Other Investing Cash Flow Items, Total | -241.4 | -199.5 | -17.2 | 0.1 |
Cash From Financing Activities | -244.2 | -127.8 | -140.6 | -73.8 |
Total Cash Dividends Paid | -101.2 | -101.2 | -73.1 | -73.1 |
Issuance (Retirement) of Stock, Net | -157.2 | -111.3 | -17.4 | -2.5 |
Issuance (Retirement) of Debt, Net | 14.3 | 84.8 | -50.1 | 1.8 |
Foreign Exchange Effects | 38.7 | 55.2 | 39.2 | 12.8 |
Net Change in Cash | -258.5 | -274 | 416 | 81.4 |
Financing Cash Flow Items | -0.1 | -0.1 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Biomerieux Company profile
About BioMerieux SA
Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, BioMerieux SA revenues increased 8% to EUR3.38B. Net income applicable to common stockholders increased 49% to EUR601.1M. Revenues reflect Microbiology segment increase of 12% to EUR1.06B, Molecular Biology segment increase of 5% to EUR1.27B, Europe & Middle East & Africa (EMEA) (Region) segment increase of 10% to EUR1.12B, America segment increase of 5% to EUR1.67B.
Equity composition
9/2017, 3-for-1 stock split (Factor: 3).
Industry: | Laboratory Diagnostic & Testing Substances |
376, chemin de l'Orme
CRAPONNE
AUVERGNE-RHONE-ALPES 69280
FR
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com